RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases. Our cutting-edge science is fully focused on developing …

RAPT Therapeutics is focused on the development of therapies for patients with significant unmet needs in inflammatory and immunologic diseases. Utilizing our deep and proprietary expertise in …

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and …

Dec 31, 2024 · RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results March 06, 2025 SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT …

Dec 31, 2023 · RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 07, 2024 Company maintains solid cash position of $158.9 million SOUTH SAN FRANCISCO, Calif., …

Our proprietary drug discovery and development engine has identified several immune drivers that have the ability to be “tuned down” to suppress an overactive immune response in inflammatory diseases. …

RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications November 16, 2020 -Evidence of Monotherapy and Combination Activity …

Sep 30, 2025 · RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights November 06, 2025 - Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced …

Oct 21, 2025 · In addition, RAPT has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of its common stock at the public offering price, less underwriting …

Oct 27, 2025 · RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies October 27, 2025 Trial initiation in food allergy follows promising results …